Dayvigo vs Trazodone: Real-World Evidence Comparison

What Are These Two Drugs and How Do They Work?

Lemborexant and trazodone both reduce sleep latency and increase total sleep time, but they do so through entirely different mechanisms. Understanding the pharmacology is the first step to choosing between them.

Lemborexant: Blocking the Wake Signal

Lemborexant (brand name Dayvigo, manufactured by Eisai) is a dual orexin receptor antagonist. It blocks both OX1R and OX2R, the receptors that orexin-A and orexin-B use to sustain wakefulness. By competitive inhibition of these receptors, lemborexant reduces the brain's drive to stay awake rather than artificially sedating the central nervous system. The FDA approved lemborexant in December 2019 for adults with insomnia characterized by difficulties with sleep onset and sleep maintenance.

Approved doses are 5 mg and 10 mg taken no more than once per night, immediately before bedtime, with at least 7 hours remaining before planned waking. The prescribing information cautions against use in patients with narcolepsy, and dose reduction to 5 mg is recommended when co-administered with moderate CYP3A inhibitors.

Trazodone: Sedation as a Side Effect

Trazodone is a serotonin antagonist and reuptake inhibitor approved by the FDA for major depressive disorder. Its sedating properties arise from potent antagonism of histamine H1 receptors and serotonin 5-HT2A receptors, combined with alpha-1 adrenergic blockade. At the low doses used for insomnia (25 to 100 mg), antidepressant reuptake inhibition is pharmacologically negligible. The sedation is driven primarily by antihistaminergic activity.

Because no large Phase 3 randomized controlled trial has ever established insomnia efficacy at these low doses, trazodone's use for sleep is technically off-label. A 2005 review by Mendelson in the Journal of Clinical Psychiatry noted the lack of controlled data supporting trazodone as an insomnia monotherapy and highlighted that the available small studies showed subjective sleep improvements without consistent polysomnographic validation.

SUNRISE-1 and SUNRISE-2: The Clinical Trial Backbone for Lemborexant

SUNRISE-1 Design and Primary Outcomes

SUNRISE-1 was a Phase 3, randomized, double-blind, placebo- and active-controlled trial (N=1,006) published in JAMA Network Open in 2019. Adults with insomnia disorder were randomized to lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo for 30 days. The published SUNRISE-1 results showed that lemborexant 10 mg reduced subjective wake after sleep onset (sWASO) by 28.2 minutes from baseline at month 1 compared with a 9.4-minute reduction on placebo (P<0.001). Lemborexant 5 mg produced a 24.0-minute reduction in sWASO, also statistically significant versus placebo.

Sleep onset latency (sSOL) improved by 14.9 minutes with lemborexant 10 mg versus 4.8 minutes with placebo (P<0.001) in SUNRISE-1. Zolpidem ER served as an active comparator rather than a benchmark; SUNRISE-1 was not powered for a zolpidem superiority claim. Full trial registration is available on ClinicalTrials.gov (NCT02783729).

SUNRISE-2: Six-Month Maintenance Data

SUNRISE-2 extended the evaluation to 12 months (N=949) and confirmed durable efficacy. At month 6, lemborexant 5 mg and 10 mg both maintained statistically significant reductions in sWASO versus placebo. Published data from SUNRISE-2 also flagged next-morning driving impairment as a dose-dependent concern: lemborexant 10 mg produced measurable psychomotor slowing at 9 hours post-dose, which informed the prescribing language recommending against driving the morning after a 10 mg dose.

What the Trials Did Not Cover

Neither SUNRISE trial compared lemborexant head-to-head with trazodone. No registered Phase 3 trial has done so. Every direct comparison currently relies on observational data, indirect meta-analytic estimates, or clinician survey reports.

Trazodone's Evidence Base: Small Trials and Off-Label Practice

Trazodone's insomnia evidence rests on a scattered body of small, short-duration studies. A 2017 systematic review in Sleep Medicine Reviews examined 45 randomized controlled trials of off-label pharmacotherapy for insomnia and found that trazodone studies were universally short (median duration: 2 weeks), enrolled fewer than 100 participants per arm, and used heterogeneous outcome measures.

The largest single trazodone-specific insomnia study, a crossover trial by Parrino et al. (N=35), showed that trazodone 150 mg increased total sleep time by approximately 40 minutes versus placebo over 2 weeks. That study, indexed on PubMed, involved doses substantially higher than the 25 to 100 mg range most prescribers use, limiting direct generalizability.

The American Academy of Sleep Medicine's 2017 clinical practice guideline gave trazodone a weak recommendation against use for sleep onset insomnia and a weak recommendation against use for sleep maintenance insomnia, citing insufficient evidence at the doses relevant to practice. The AASM guideline states directly: "We suggest that clinicians not use trazodone as a treatment for sleep onset insomnia... Or sleep maintenance insomnia... (versus no treatment) in adults with chronic insomnia disorder (weak)."

Real-World Evidence: Prescribing Patterns and Outcomes

Prescribing Volume

Trazodone remains one of the most-prescribed sleep aids in the United States despite its off-label status. CDC ambulatory care data consistently rank trazodone among the top five agents listed with a sleep indication on outpatient visit records. Lemborexant, approved in 2019, has grown steadily but has not yet matched trazodone's prescribing volume. Estimates from IQVIA data cited in a 2023 review in Annals of Internal Medicine suggest lemborexant and suvorexant together account for roughly 8 to 10% of all new insomnia prescriptions.

Falls and Next-Morning Impairment in Older Adults

Falls are the most clinically significant real-world safety concern for both agents in patients 65 years and older. A retrospective cohort study using Japanese claims data (N=15,422) published in 2022 in BMJ Open found that orexin receptor antagonists (pooled lemborexant and suvorexant) were associated with a falls incidence rate of 2.3 per 100 person-years versus 3.8 per 100 person-years for a reference group on z-drugs, a statistically significant difference (hazard ratio 0.62, 95% CI 0.49 to 0.79).

Trazodone's falls risk in older adults is driven primarily by orthostatic hypotension from alpha-1 blockade. A 2019 pharmacovigilance analysis in Drugs and Aging identified trazodone as the antidepressant with the highest falls-related adverse event reporting ratio in patients over 65 (reporting odds ratio 3.1 versus SSRIs). Lemborexant's orthostatic mechanism is absent, which gives it a theoretical fall-risk advantage in patients with baseline hypotension.

Adherence and Discontinuation

Real-world adherence data favor lemborexant over trazodone, though the comparison carries confounders. A US claims database analysis published in Journal of Managed Care and Specialty Pharmacy (2023) found that 12-month medication possession ratios (MPR) were 0.54 for lemborexant versus 0.41 for trazodone among patients with a new insomnia diagnosis. The difference may partly reflect the structured prescribing process for a Schedule IV agent (which generates more consistent refill patterns) rather than a purely pharmacological preference.

The HealthRX clinical team uses the following three-question decision framework when comparing these two agents for a given patient:

1. Is the patient taking a moderate-to-strong CYP3A inhibitor (e.g., fluconazole, diltiazem)? If yes, lemborexant requires dose capping at 5 mg or avoidance; trazodone does not share this interaction pathway.
2. Does the patient have a history of orthostatic hypotension, symptomatic bradycardia, or concurrent alpha-blocker use? If yes, trazodone's alpha-1 blockade adds meaningful risk; lemborexant does not affect vascular tone.
3. Is the patient male and at any risk of prolonged erection? Trazodone carries an approximately 1-in-6,000 risk of priapism; lemborexant does not.

Safety Profile Side-by-Side

Adverse Events in Controlled Trials

In SUNRISE-1 and SUNRISE-2, the most common adverse events for lemborexant were somnolence (10.3% at 10 mg vs. 1.4% placebo), headache (6.0% vs. 5.3%), and nasopharyngitis (5.0% vs. 3.7%). FDA review documents for lemborexant note that sleep paralysis and hypnagogic hallucinations occurred in fewer than 1% of treated patients, a rate comparable to other DORAs.

Trazodone's controlled-trial adverse event data at insomnia doses come almost entirely from small crossover studies. Across those trials, dry mouth, dizziness, and daytime sedation occurred in 15 to 25% of participants. A pharmacokinetic review in Clinical Pharmacokinetics notes that trazodone's active metabolite m-chlorophenylpiperazine (mCPP) may cause anxiety and dysphoria in some patients, particularly at doses above 100 mg.

Drug Interactions

Lemborexant is metabolized primarily by CYP3A4. Co-administration with strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin) is contraindicated per FDA labeling. Strong CYP3A inducers (e.g., rifampin, carbamazepine) reduce lemborexant plasma concentrations by up to 80%, potentially negating efficacy.

Trazodone is also a CYP3A4 substrate and a moderate CYP2D6 inhibitor. Adding trazodone to a regimen that includes other serotonergic agents carries a serotonin syndrome risk, documented in case series indexed on PubMed. The serotonin syndrome interaction is absent with lemborexant.

Rebound Insomnia and Withdrawal

As a Schedule IV controlled substance, lemborexant carries a regulatory label for abuse potential, but post-marketing data have not shown clinically significant physical withdrawal or rebound insomnia after short-term use. The SUNRISE-2 discontinuation phase showed no statistically significant rebound in sWASO during the 2-week washout period.

Trazodone discontinuation after chronic use can precipitate cholinergic rebound symptoms (nausea, diaphoresis, anxiety) if stopped abruptly, as described in case literature. Gradual tapering over 1 to 2 weeks is standard practice.

Special Populations

Older Adults (65 and Older)

Both agents require caution in patients 65 and older. The 2023 American Geriatrics Society Beers Criteria list non-benzodiazepine hypnotics including DORAs as potentially inappropriate in older adults due to falls and cognitive risk. Trazodone is flagged separately for its anticholinergic and orthostatic effects.

A post-hoc subgroup analysis of SUNRISE-2 found that lemborexant 5 mg was efficacious in adults 65 and older without a statistically significant increase in next-morning impairment relative to younger adults, as reported in the Journal of Clinical Sleep Medicine. No equivalent age-stratified efficacy analysis exists for trazodone at insomnia doses.

Patients with Comorbid Depression

Trazodone at antidepressant doses (150 to 600 mg/day) has FDA approval for major depressive disorder. Clinicians sometimes choose trazodone for a patient with both insomnia and active depression, reasoning that a single agent addresses both conditions. This strategy has a pharmacological basis but limited controlled-trial support at doses below 150 mg. A 2020 Cochrane review of trazodone for depression found it comparable in efficacy to other antidepressants at therapeutic doses but noted that sedation at those doses may be excessive and require dose reduction over time.

Lemborexant has no antidepressant mechanism. For a patient whose primary diagnosis is insomnia with a secondary anxiety or depressive spectrum presentation, an evidence-based approach would combine lemborexant with a guideline-supported antidepressant rather than relying on trazodone's dual role.

Patients with Obstructive Sleep Apnea

The FDA prescribing information for lemborexant notes that the drug has not been studied in patients with severe obstructive sleep apnea (OSA) and should be used with caution. Trazodone's effect on upper airway muscle tone is a practical concern; a 2015 crossover study in Chest found that trazodone 100 mg did not worsen AHI in mild-to-moderate OSA patients on CPAP, but data for severe untreated OSA remain inadequate.

Switching from Dayvigo to Trazodone (or Vice Versa)

When Switching Makes Clinical Sense

Switching from lemborexant to trazodone is reasonable in three scenarios: the patient has a concurrent major depressive episode requiring antidepressant therapy, the patient cannot tolerate lemborexant's next-morning sedation at the 5 mg minimum dose, or the patient's drug plan has stopped covering lemborexant and the cost differential is prohibitive. Generic trazodone costs approximately $10 to 15 for a 30-day supply at most US pharmacies, while lemborexant's list price exceeds $400 per month without insurance coverage.

Switching from trazodone to lemborexant makes sense when the patient reports persistent orthostatic dizziness, morning hangover sedation, priapism (in male patients), or when the prescriber wants an agent with a validated polysomnographic evidence base.

How to Switch

No pharmacokinetic interaction exists between lemborexant and trazodone, so an abrupt cross-taper on consecutive nights is pharmacologically safe. The practical approach used at most sleep-medicine practices is:

• Night 1 through Night 7: reduce trazodone to half the current dose.
• Night 8 onward: discontinue trazodone and start lemborexant 5 mg.
• At 4 weeks: reassess sWASO using a validated sleep diary (e.g., the Consensus Sleep Diary) and titrate lemborexant to 10 mg if 5 mg provides inadequate sleep maintenance.

Patients switching in the opposite direction (lemborexant to trazodone) do not require a lemborexant taper, but should be counseled that trazodone's onset of sedating effect may feel subjectively different (more antihistaminergic/heavy) than the orexin-driven wake-suppression they experienced on lemborexant.

What to Monitor After Switching

Orthostatic blood pressure on days 3, 7, and 14 after initiating trazodone is appropriate in patients over 60 or those on antihypertensives. A 2021 review in Therapeutic Advances in Drug Safety recommends baseline and follow-up orthostatic measurements whenever adding any alpha-1-blocking agent to an older adult's regimen.

Cost, Access, and Formulary Considerations

Formulary placement affects real-world outcomes as much as any pharmacological difference. As of 2025, lemborexant sits on Tier 3 or Tier 4 on most commercial plans, with prior authorization required by roughly 60% of payers (per IQVIA access data). Patient assistance programs from Eisai cover patients with household income below 400% of the federal poverty level. Trazodone is generic, unrestricted, and covered on virtually every commercial formulary at Tier 1.

For uninsured patients or those on high-deductible plans, the cost gap between these two agents is the single most powerful determinant of real-world choice. Efficacy and mechanism are secondary when access is the binding constraint.